Logo

Synthetic Genetics Company Codon Closes $20M in Series B VC Round

Dec 19, 2006
NEW YORK (GenomeWeb News) — Synthetic genetics company Codon Devices has pocketed $20 million in a Series B round of venture capital financing, Codon said today.
 
Codon CEO John Danner said the company will use the cash to develop its BioFAB production platform, which uses informatics, robotics, and sequencing technology to synthesize gene codes.
 
In July Codon reported it had built a 35-kilobase gene cluster for the pharmaceutical company Microbia.

 

The company also plans use the money to expand its protein and metabolic engineering and will push ahead with a global sales agenda.
 
Highland Capital Partners led the round. Contributors included Alloy Ventures, Flagship Ventures, Khosla Ventures and Kleiner Perkins Caufield & Byers.

Breaking News
The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.